Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

July 15, 2023

Study Completion Date

August 5, 2023

Conditions
Psoriasis
Interventions
DRUG

Remsima

The patient will be given one Injection of REMSIMA 120 mg subcutaneously at week 0, 1, 2, 3, 4 and then every 2 weeks i.e., at 6, 8, 10 and 14 weeks. If the weight of the patient is \>80 kg, 2 injections will be given.

Trial Locations (1)

Unknown

Ghurki Hospital, Lahore

All Listed Sponsors
lead

Ghurki Trust and Teaching Hospital

OTHER

NCT06043752 - Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis | Biotech Hunter | Biotech Hunter